Kadmon’s ROCKstar Is Rising On GvHD Therapy Data
Belumosudil Shines In Study
Kadmon’s treatment for graft-versus-host disease, belumosudil continues to perform well in its pivotal ROCKstar study, setting the stage for a US filing under the FDA’s pilot Real-Time Oncology Review program.
